Kornimate/medical-research-clean huggingface dataset:
hydroxychloroquine treatment of dry eyes in patients with primary sjögren's syndrome

Conditions: Autoimmune Diseases; Sjogren's Syndrome; Dry Eye

Summary: primary sjögren syndrome is one of the most prevalent autoimmune diseases that present with dry eye and dry mouth. but there is no proven effective treatment for sjögren syndrome patient. the relation between toll-like receptor (tlr) and the pathogenesis of sjögren syndrome has been reported. hydroxychloroquine is tlr7 and tlr9 antagonist. a few studies have been reported the effectiveness of hydroxychloroquine for sjögren syndrome but no randomized controlled study has been done. so the investigators evaluate the effectiveness and safeness of hydroxychloroquine for primary sjögren syndrome by randomized controlled study (hydroxychloroquine 300 mg once daily p.o. group (n = 30) versus placebo group (n = 30).


Eligibility criteria:
inclusion criteria: * patient who is diagnosed with primary sjögren syndrome according to american/european consensus group (aecg) criteria * patient with the ability to give informed, dated and signed consent before the beginning of any proceedings related to the trial exclusion criteria: * previous treated by hydroxychloroquine but enough washout time after discontinuance of treatment, patient can be enrolled. (2 wks) * known cardiac disease, respiratory disease, renal disease, gastrointestinal disease (except gerd) * diabetes mellitus * psoriasis * known drug allergy or hypersensitivity * previous or ongoing treatment by any drugs (include topical drug) which have effect on lacrimal system. but enough washout time after discontinuance of treatment, patient can be enrolled. (cf. ssri, anti-histamine, pilocarpine, etc.) * angle closer glaucoma * patient who underwent previous intraocular surgery * macular disease * previous or ongoing treatment by drug which could have effect on macula * pregnancy * planning to get pregnant

Keywords: autoimmune diseases sjogren's syndrome hydroxychloroquine
study to investigate the safety and clinical activity of gsk3326595 and other agents to treat myelodysplastic syndrome (mds) and acute myeloid leukemia (aml)

Conditions: Neoplasms

Summary: this study will evaluate the safety, tolerability, and clinical activity of gsk3326595 in participants with relapsed and refractory mds, chronic myelomonocytic leukemia (cmml), and aml. the study will be conducted in 2 parts: part 1 will determine the clinical benefit rate (cbr) of gsk3326595 in monotherapy and part 2 will be expanded to study gsk3326595 in combination with 5-azacitidine which will be composed of a dose escalation phase followed by dose expansion cohort of gsk3326595.


Eligibility criteria:
inclusion criteria: * males and females greater than or equal to (\>=)18 years of age (at the time consent is obtained). * diagnosis of mds, cmml or aml * eastern cooperative oncology group (ecog) performance status score of 0 or 1 or 2 * adequate organ function * a woman of childbearing potential (wocbp) must have a negative highly sensitive serum pregnancy test within 7 days before the first dose of study intervention. exclusion criteria: * history of, or known, central nervous system (cns) involvement * prior solid organ transplantation * known allergies, hypersensitivity, or intolerance to gsk3326595 or 5-azacitidine or its excipient * prior therapy with any protein arginine methyl transferase 5 (prmt5) inhibitor * history of a second malignancy, excluding non-melanoma skin cell cancer, within the last three years * active severe or uncontrolled infection * history of optic nerve neuropathy or neuritis. * history of sensitivity to any of the study medications, or components thereof, or a history of drug or other allergy that, in the opinion of the investigator or medical monitor, contraindicates their participation.

Keywords: acute myeloid leukemia myelodysplastic syndrome chronic myelomonocytic leukemia gsk3326595 5-azacitidine
detection no invasive of a silent myocardial ischemia

Conditions: Silent Myocardial Ischemia; Type 2 Diabetes

Summary: the pathophysiological features of myocardial diabetic subject combined with cardiac autonomic neuropathy were behind the quietness of myocardial ischemia, known as silent myocardial ischemia (ims). these patients have the risk to remain asymptomatic until the sudden onset of a myocardial infarction, or even sudden death. that is why the investigators want to evaluate the contribution of non-invasive tools to stand in the diagnosis of ims patients with diabetes type 2, asymptomatic heart on map: technical myocardial speckle tracking in studying strains overall average left ventricular (longitudinal, circumferential and radial) measured in 2d and 3d at rest, compared to stress echocardiography with dobutamine (esd)


Eligibility criteria:
inclusion criteria: * with at least two cardiovascular risk factors including: hypertension, dyslipidemia, smoking active or interrupted for less than 3 years, family history (relatives of the 1st degree) accident major cv before 60. * or whatever the level of risk factors: peripheral artery disease and / or carotid atherosclerosis, or proteinuria exclusion criteria: * valvular heart disease (severe to moderate valvular ) , hypertrophic , dilated , chronic lung * history of cardiotoxic chemotherapy * atrioventricular blocks of degree * asthma * recent stroke within a month * bilateral carotid stenosis tight * glaucoma untreated narrow angle * subject to exclusion period (determined by a previous study or in progress) * inability to give informed about information * patient under judicial protection * patient guardianship or curatorship * current pregnancy (women of childbearing age ) * breastfeeding
study assessing efficacy of zarnestra™ combined with tamoxifen in patients with advanced or metastatic breast cancer

Conditions: Breast Neoplasms

Summary: the purpose of this study is to evaluate the objective response rate when zarnestra is added to treatment with tamoxifen


Eligibility criteria:
inclusion criteria: * histologically proven, metastatic or locally advanced inoperable breast cancer * tumor considered potentially hormone-sensitive, i.e. presence by ihc of hormone receptors for estrogens (er+ for more than 10% of cells) and/or progesterone (pg+ for more than 10% of cells) or both. this expression may have been detected on the primary tumor or at a metastatic site. the method used will be reassessed by ihc if it involves a radioligand technique whenever it is possible to obtain histological material. * progressing on treatment with tamoxifen, given either as adjuvant treatment or for advanced/metastatic breast cancer. any previous treatment with a steroidal or nonsteroidal antiaromatase in a neo-adjuvant, adjuvant or metastatic situation is permitted. likewise, any previous treatment with chemotherapy and/or herceptin in a nonmetastatic situation is permitted. * post-menopausal patients * age \> 18 years * at least one measurable lesion according to the response evaluation criteria for solid tumors (recist) criteria; for patients who only have bone metastases, an evaluable non-irradiated lytic lesion is required * performance status (who): ps ≤ 2 (appendix 1). * laboratory tests in accordance with the following criteria: neutrophils ≥ 2x109/l,platelets ≥ 100x109/l,hemoglobin ≥ 10 g/dl, asat, alat ≤ 2.5 n , or \< 5 n when liver metastasis,bilirubin ≤ 1.5 n creatinin ≤ 1.5 n * signed, written consent before any study-related procedure exclusion criteria: * men * pre-menopausal patients who are not receiving concurrent lhrh agonist therapy * er- and pr-negative patients * contraindication to antiestrogens (thromboembolic risk) or zarnestra * non metastatic tumor susceptible to management by radiotherapeutic and/or surgical means * t4d inflammatory tumor (pev 2 or 3). * short-term, life-threatening lesions: hepatic invasion \> 1/3 of liver volume, pulmonary lymphangitis, uncontrolled cerebral metastases, carcinomatous meningitis * sensory neuropathy \> or = grade 1 (who) * previous history of uncontrolled cancers or controlled for less than 5 years, except basal cell skin cancers and in situ cancers of the cervix. * chronic diseases (somatic or psychiatric) with a poor prognosis * subjects with enzyme-inducing anti-convulsants (e.g., phenytoin, phenobarbital, carbamazepine) : this treatment is not permitted while taking zarnestra * patients who, for family, social, geographic or psychological reasons, could not be followed up correctly.

Keywords: breast neoplasms zarnestra tamoxifen estrogen receptor progesterone receptor
molecular landscape of microvascular inflammation in kidney allografts

Conditions: Kidney Rejection Transplant

Summary: microvascular inflammation in kidney allografts has been widely reappraised in the recent update of banff classification. there is a critical need to better understand the pathophysiological mechanisms associated with the various phenotypes of microvascular inflammation that are observed in kidney transplants, particularly in order to develop targeted therapeutic approaches.

antibody-mediated rejection is a major cause of graft failure in kidney transplant recipients. the diagnostic criteria for antibody-mediated rejection have undergone significant changes since their initial definition in the international banff classification system. the banff 2022 classification update reappraises lesions of microvascular inflammation and identifies new phenotypes for cases with microvascular inflammation. however, pathophysiological mechanisms associated with microvascular inflammation in kidney allografts are still poorly understood, thus hampering the development of efficient treatments. the aims of this study are: 1. to decipher the spatial immune-molecular landscape of microvascular inflammation in kidney allografts. 2. to compare the characteristics of this landscape in different clinical scenarios. the investigators will use a multimodal phenotyping approach including histological analyses and multiplex immunostainings, bulk transcriptomic analyses and spatial whole-transcriptome digital profiling to decipher the molecular landscape of microvascular inflammation in kidney allografts. based on these results, they will investigate its association with allograft outcomes and search for molecular targets which could benefit from targeted therapeutic strategies.

Eligibility criteria:
inclusion criteria: - adult kidney transplant recipients, with at least one kidney transplant biopsy performed and assessed according to the international banff 2022 classification, with or without lesions of microvascular inflammation exclusion criteria: * inadequate biopsy according to the banff classification * missing data for banff lesion scores, donor-specific antibody status, c4d staining * biopsies showing histological signs of ischemia-reperfusion * combined transplantation and kidney transplantation after a non-kidney solid organ transplantation
pain management in internal medicine department

Conditions: Pain

Summary: the assessment of pain management in internal medicine department.

the experimental procedure - a literature review of the management of pain in internal departmnet and after that defining and identifying gaps between the pain management practice recommendations in the literatureareas to that of the departmnet. determining the educational processes for the medical team, in initiation treatment for pain and pain assessment. as well, obtain quality indicators to monitor pain management. assessment of attitudes, knowledge and tools for pain management team before the educational process and afterwards. in patients with mild pain or above, a combination of quantitative and qualitative tools will assess the pain and its treatment along the hospitalization in the internal medicine ward.

Eligibility criteria:
inclusion criteria: * all patient with mild pain and above exclusion criteria: * none
age/srage ratio in diabetic periodontitis

Conditions: Periodontitis, Diabetes Mellitus Type 2

Summary: the goal of this observational study is to learn about some molecules in the disease mechanism of type 2 diabetes and periodontitis. there are end products inside the body called ages and their receptors binding to them especially (srage, rage) in people with diabetes in hyperglycemic state.these molecules are important also in periodontitis (the disease of teeth that may end with exfoliation of the tooth). diabetes and periodontitis enhance each other's disease-causing effects. both is chronic inflammatory diseases and il-17 is another molecule having role in this process. totally 64 men and women aged between 27-60 included in the study. study groups were : 1.participants with healthy teeth and no diabetes, 2. participants with periodontitis without diabetes, 3.participants with periodontitis and controlled diabetes, 4.participants with periodontitis and uncontrolled diabetes (6.5% and fasting blood sugar levels \<200 mg/dl). researchers got saliva and gingival crevicular fluid (gcf) samples from diseased teeth and examined age, srage, il-17 levels. gcf is a fluid around the crevice of the theeth with different characteristics from saliva. as a result age/srage ratio and il-17 levels of diseased groups were higher than healthy group, while srage levels were significantly lower in gcf samples. researchers concluded that gcf and saliva age/srage ratio may represent as a biomarker in periodontitis patients with uncontrolled diabetes.


Eligibility criteria:
inclusion criteria: * having interdental attachment loss in at least two non-adjacent teeth, or with \>3 mm of attachment loss in the buccal or palatal/lingual region with \>3 mm probing depth in at least two teeth for periodontitis groups. * having minimum 5mm or more pocket depth in at least 6 periodontal pockets. * hba1c value ≤ 6.5% and fasting blood sugar levels \<200 mg/dl for the controlled diabetes group. * hba1c value \> 6.5% and fasting blood sugar levels \> 200 mg/dl for uncontrolled diabetes group. exclusion criteria: * having periodontal treatment in the last six months; * participants with smoking habit or history; and * usage of medicine that may affect study results (mouthwash, antibiotics, corticosteroid, statins etc.) three months before collecting dental plaque and gcf samples. * lactating or pregnant patients * patients with systemic diseases other than type 2 diabetes.
post covid-19 vaccination development or flare of ard

Conditions: COVID-19; Vaccination; Infection; Rheumatic Diseases

Summary: many patients develop autoimmune diseases after covid-19 vaccination, whether related to the vaccination or not, is still under study. this study will describe potential flare of ard after covid-19 vaccination, whether it leads to activity or new msk manifestations development.

-in this study: patients with known diagnosed rheumatic diseases who are vaccinated (one or full doses) of any type of covid-19 vaccines will be enrolled. new ard and prevalence of different msk manifestations after covid-19 vaccinations also will be reported. the prevalence of flare of ard after covid-19 vaccinations will be dteremined. also we will compare between different types and doses of covid-19 vaccinations in inducing ard or flares. study design: cross sectional study target population: any patient with pre-existing received any vaccination against covid-19 visiting rheumatology outpatient clinic. -any patient develops msk manifestations after covid-19 vaccination. the disease activity sataus will be measured according to the type of rheumatic disease. for ra , disease activity score28 will be used, in lupus: sledai, in behcet : bdcaf, in spa: basdai.

Eligibility criteria:
inclusion criteria: age above 18 years vaccinated against covid-19 (one dose or fully vaccinated) exclusion criteria: receiving other vaccine e.g influenza less than 18 years old
comparison of harmonic scalpel and ligasure devices in laparoscopic morbid obesity surgery

Conditions: Morbid Obesity

Summary: comparison of harmonic scalpel and ligasure devices in laparoscopic morbid obesity surgery especially in gastric bypass surgery patients.

the investigators' department performs 150 gastric bypass surgeries annually. surgeons use both harmonic scalpel and ligasure sealing device in cases. aim is to compare both of these devices over coming each other. benefits ease of these devices are compared.

Eligibility criteria:
inclusion criteria: * obesity * bmi over 40 kg/m\^2 exclusion criteria: * normal bmi cases

Keywords: laparoscopy obesity harmonic scalpel ligasure
to look or not to look at the needle during vaccination

Conditions: Vaccination

Summary: it is common for people to advise individuals undergoing vaccination to look away from the needle to make them hurt less and be less scary. however, this advice is not backed up by research evidence. the purpose of this study is to learn about how looking away vs. looking at the needle during vaccination makes people feel. people will be randomized to 1 of 2 groups: look at the needle, look away. then they will undergo vaccination and report on pain and fear experienced.

it is common for people to advise individuals undergoing vaccination to look away from the needle to make them hurt less and be less scary. however, this advice is not backed up by experimental research evidence. it is possible that looking away acts as a distraction and takes attention away from the needle, thus reducing pain. however, it is also possible that looking at the needle is better because it prevents people's imaginations from making them think it is worse than it actually is. to our knowledge, this is the first first randomized study to examine the effect of looking away vs. looking at the needle on pain and fear experienced during vaccinations. adult university students undergoing routine flu vaccination will be included.

Eligibility criteria:
inclusion criteria: * undergraduate and graduate students at the university of toronto's leslie dan faculty of pharmacy undergoing flu vaccination exclusion criteria: * less than 18 years of age or prior participation in the trial

Keywords: vaccination pain fear psychological intervention
study of the effect of pneumococcal conjugate vaccine (pcv) on immunogenicity of pentacel™

Conditions: Diphtheria; Tetanus; Haemophilus Infection; Pertussis; Polio

Summary: this study is designed to evaluate in a controlled manner the effect of prevnar® on the immune responses of pentacel™ primary objective - stage i: to compare the immune responses elicited by an infant series of pentacel™ when given at different times from or concurrently with a pneumococcal conjugate vaccine (prevnar®). primary objective - stage ii: to compare the immune responses elicited by a 4th dose of pentacel™ when given at different times from or concurrently with prevnar®.

this is a 2-staged study. stage i of this study is designed to compare the immune responses elicited by an infant series (3 doses) of pentacel™ when given at different times from or concurrently with prevnar®. stage ii is designed to describe the immune responses elicited by a 4th dose of pentacel™ (all antigens) when given at different times from or concurrently with prevnar®.

Eligibility criteria:
inclusion criteria : * healthy infants 2 months (≥ 42 days and ≤ 89 days) of age. * infants with at least 36 weeks of gestation at delivery. * must have received 1 dose of hepatitis b vaccine (with that dose at least 15 days before the administration of study vaccines). * able to attend the scheduled visits and to comply with the study procedures. * parent or legal guardian willing to take rectal temperatures during the infant series. * parent or legal guardian has access to a telephone. * signed informed consent from parent or legal guardian obtained before the 1st study intervention. * able to obtain at least 1.5 ml of blood sample prior to dose 1. exclusion criteria : * clinically significant findings on review of systems (determined by investigator or sub-investigator to be sufficient for exclusion). * known or suspected hypersensitivity to any component of the study vaccine to be administered. * known or suspected impairment of immunologic function or receipt of immunosuppressive therapy or immunoglobulin since birth. * known human immunodeficiency virus (hiv)-positive mother or child. * personal or immediate family history of congenital immune deficiency. * developmental delay or neurologic disorder. * chronic medical, congenital, or developmental disease. * participation in any other clinical trial. * any condition which, in the opinion of the investigator, would interfere with the evaluation of the vaccine or pose a health risk to the subject. * prior history of having received any acellular pertussis- (dtap) or whole cell pertussis- (dtwp) based combination vaccines, haemophilus influenzae type b (hib)-conjugate, poliovirus, or pneumococcal conjugate vaccines.

Keywords: pertussis whooping cough diphtheria tetanus haemophilus influenzae poliovirus types 1, 2, and 3.
the effects of working memory training in children with attention-deficit/hyperactivity disorder

Conditions: Attention Deficit Disorder With Hyperactivity; Psychophysiology

Summary: previous studies indicated that children with attention-deficit/hyperactivity disorder (adhd) often suffer from deficits in executive function, such as attentional control, inhibition, and working memory. one of these executive functions, working memory, plays a critical role in academic performance and classroom behavior. working memory is essential for performing complex cognitive tasks such as comprehension, learning, and reasoning. several studies have shown that training of working memory has positive effects for adhd and other cognitive disorder in children. however, transfer effects across studies appear to be variable and inconsistent. event-related potentials can be a useful tool to gain insights into such mechanism. therefore, the aim of the present study is to investigate both near and far transfer effects of n-back training in children with adhd. in addition, the recording and analysis of event-related potentials will be adopted while children with adhd perform the complex visuo-spatial and phonological working memory tasks.


Eligibility criteria:
inclusion criteria: * adhd diagnosed according to criteria specified in diagnostic and statistical manual of mental disorders (dsm-5) * aged between 8 and 10 years * intelligence quotient \> 80 (based on test of nonverbal intelligence-third edition) * had normal or corrected-to-normal vision * right-handed exclusion criteria: * diagnosis of clinically significant oppositional defiant disorder, autistic spectrum disorders, asperger's syndrome or depression * history of seizures